Clearside Biomedical Announces Presentations at the American

ALPHARETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal

Related Keywords

United States , San Francisco , California , American , Belzupacap Sarotalocan , Arshadm Khanani , Markr Barakat , Jenny Kobin Remy Bernarda , Triamcinolone Acetonide Suprachoroidal , Rahuln Khurana , Suprachoroidal Administration , American Academy Of Ophthalmology , Nasdaq , Va Physician , Exchange Commission , Clearside Biomedical Inc , American Academy , Axitinib Injectable Suspension , Uveitic Macular Edema , Suprachoroidal Delivery , Gene Therapy , Late Breaking Developments , Targeted Investigational Therapy , Choroidal Melanoma , Suprachoroidal Space , Injection Platform , Clearside Biomedical , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Periodic Reports , Media Contacts , Region ,